Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines
- PMID: 22153001
- DOI: 10.1016/j.ijid.2011.10.002
Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines
Abstract
Objective: Comparison of a fractional inactivated poliovirus vaccine (IPV) dose administered intradermally (ID) to a full dose administered intramuscularly (IM).
Methods: Healthy Filipino infants were randomized to receive IPV as either a fractional (1/5(th)) dose ID by needle injection or a full dose IM at 6, 10, and 14 weeks and a booster at 15-18 months of age. Pre- and post-vaccination anti-polio 1, 2, and 3 titers were estimated. Adverse events were monitored throughout the study.
Results: Following primary series vaccination, anti-polio 1, 2, and 3 titers were ≥8 (1/dil) in 99-100% of participants, and the ID route was non-inferior to the IM route. Depending on the study group, antibody persistence was detected in 83-100% of participants, and the booster dose resulted in a strong anamnestic response in all groups. The incidence of adverse events in each group was similar, except for injection-site erythema (higher in the ID group).
Conclusions: Primary series and booster vaccination of a fractional IPV dose administered by the ID route was highly immunogenic and well tolerated. These data confirm the medical validity of using fractional ID doses of IPV. The programmatic feasibility of implementing affordable mass vaccination programs based on this delivery mode has yet to be established.
Trial registration: ClinicalTrials.gov NCT00604058 NCT00885157.
Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.Pediatr Infect Dis J. 2012 Jan;31(1):e24-30. doi: 10.1097/INF.0b013e318242460a. Pediatr Infect Dis J. 2012. PMID: 22157567
-
Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.Vaccine. 2006 May 29;24(22):4727-36. doi: 10.1016/j.vaccine.2006.03.032. Epub 2006 Mar 24. Vaccine. 2006. PMID: 16616973 Clinical Trial.
-
One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.Int J Infect Dis. 2007 Nov;11(6):488-95. doi: 10.1016/j.ijid.2007.01.006. Epub 2007 Mar 8. Int J Infect Dis. 2007. PMID: 17349809 Clinical Trial.
-
New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).Ann Pharmacother. 2010 Mar;44(3):515-23. doi: 10.1345/aph.1M468. Ann Pharmacother. 2010. PMID: 20197476 Review.
-
Comparison of equivalent fractional vaccine doses delivered by intradermal and intramuscular or subcutaneous routes: A systematic review.Travel Med Infect Dis. 2021 May-Jun;41:102007. doi: 10.1016/j.tmaid.2021.102007. Epub 2021 Mar 9. Travel Med Infect Dis. 2021. PMID: 33711425 Review.
Cited by
-
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.N Engl J Med. 2024 Nov 28;391(21):2003-2013. doi: 10.1056/NEJMoa2314620. Epub 2024 Sep 26. N Engl J Med. 2024. PMID: 39330966 Free PMC article. Clinical Trial.
-
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance.Pathogens. 2024 Mar 4;13(3):224. doi: 10.3390/pathogens13030224. Pathogens. 2024. PMID: 38535567 Free PMC article. Review.
-
Oral Vaccines: A Better Future of Immunization.Vaccines (Basel). 2023 Jul 12;11(7):1232. doi: 10.3390/vaccines11071232. Vaccines (Basel). 2023. PMID: 37515047 Free PMC article. Review.
-
Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication.Hum Vaccin Immunother. 2022 Dec 30;18(7):2154100. doi: 10.1080/21645515.2022.2154100. Epub 2022 Dec 28. Hum Vaccin Immunother. 2022. PMID: 36576132 Free PMC article. Review.
-
Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey.Lancet Reg Health Am. 2022 Jul;11:None. doi: 10.1016/j.lana.2022.100235. Lancet Reg Health Am. 2022. PMID: 35865654 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources

